Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Krystal Biotech (KRYS) Leases (2021 - 2025)

Krystal Biotech's Leases history spans 5 years, with the latest figure at $7.2 million for Q4 2025.

  • For Q4 2025, Leases rose 15.27% year-over-year to $7.2 million; the TTM value through Dec 2025 reached $7.2 million, up 15.27%, while the annual FY2025 figure was $7.2 million, 15.27% up from the prior year.
  • Leases for Q4 2025 was $7.2 million at Krystal Biotech, down from $7.4 million in the prior quarter.
  • Across five years, Leases topped out at $8.5 million in Q1 2022 and bottomed at $3.2 million in Q1 2021.
  • The 5-year median for Leases is $7.4 million (2021), against an average of $7.2 million.
  • The largest annual shift saw Leases skyrocketed 164.16% in 2022 before it decreased 12.62% in 2023.
  • A 5-year view of Leases shows it stood at $7.2 million in 2021, then increased by 11.26% to $8.0 million in 2022, then dropped by 12.62% to $7.0 million in 2023, then decreased by 10.63% to $6.3 million in 2024, then grew by 15.27% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Leases are $7.2 million (Q4 2025), $7.4 million (Q3 2025), and $7.7 million (Q2 2025).